Bayer AG announced today that BlueRock Therapeutics (BlueRock), a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, successfully administered the first dose of its pluripotent stem cell-derived dopaminergic neurons, named DA01, to a Parkinson’s disease patient in their open-label Phase 1 clinical study.
Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson’s disease
June 8, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022